Size the GLP-1 prescribing footprint, no IQVIA budget required.
Network-level HCP counts and patient-cohort sizing for branded GLP-1 receptor agonists. By state, specialty, ICD-10. Aggregate counts only, cell-size floored at 11. No PHI. One pre-built Scope query, results in 90 seconds. Built for pharma brand teams, DTC and consumer-health agencies, and CME providers who need the answer faster and cheaper than a syndicated report.
What this template asks
- Drug class
- GLP-1 receptor agonists
- RxNorm codes
- semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide
- ICD-10
- E11 (Type 2 diabetes mellitus), E66.9 (Obesity, unspecified), E66.01 (Morbid obesity due to excess calories)
- Rollup
- state + specialty
412,843 HCPs across 14 states
- Endocrinology18,472 (4.5%)
- Internal medicine / primary care191,220 (46.3%)
- Family medicine143,511 (34.8%)
- Bariatric medicine7,822 (1.9%)
- Cardiology9,104 (2.2%)
- TX51,204 HCPs
- FL44,721 HCPs
- CA41,330 HCPs
- NY32,876 HCPs
- PA22,103 HCPs
Sample only, anonymized. Live runs return your specified geography and time window. Aggregate counts only, no PHI.
Pharma brand teams
Compare your branded GLP-1 prescribing footprint to peer brands across regions before campaign budget is committed. Triangulate against your sales data to surface compounding-leakage risk.
DTC and consumer-health agencies
Size your audience for weight-loss and metabolic-health campaigns. HCP counts plus patient-cohort estimates by state and specialty, in 90 seconds.
CME and accredited programs
Target accredited GLP-1 programs at the specialties and regions where prescribing is concentrated. Endocrinology, primary care, bariatric, cardiology rollups out of the box.